Neuren Pharmaceuticals Limited (ASX:NEU) shares rose 0.68% on 18 September 2026 to close at A$20.68, up A$0.14 for the day. The move adds to a strong run for the stock, which is up approximately 80% over the past six months, as the market continues to reward Neuren's growing Royalty income and the launch of its first-ever Dividend program.

What Drove Neuren Shares Today

Neuren also lodged a technical ASX update (Appendix 3A.1) on 18 September 2026 clarifying that securityholders with a registered address in New Zealand who make no direct Credit election will now have their Interim Dividend withheld in NZD rather than AUD. While largely administrative, this update landed alongside continued positive sentiment following the company's H1 2026 results and dividend announcement in late August.

Company Overview

Neuren Pharmaceuticals develops drug therapies for serious neurological disorders caused by genetic abnormalities or brain injury, targeting the role of insulin-like growth Factor 1 (IGF-1) in the brain through orally administered analogs of naturally occurring peptides. The company's commercial success is anchored by DAYBUE® (trofinetide), the only approved treatment for Rett syndrome in the United States, European Union, Canada and Israel, which Neuren has exclusively licensed worldwide to Acadia Pharmaceuticals.

On 26 August 2026, Neuren announced its H1 2026 results alongside its first-ever dividend policy. The Board declared a fully franked interim dividend of 15 cents per share, representing 90% of the company's H1 2026 "Available Pool" — defined as royalty income less corporate and administration costs, after tax. The ongoing policy targets a semi-annual Payout Ratio of between 70% and 100% of this Available Pool. H1 2026 royalty income rose 29% to US$23.3 million (A$33.2 million) compared to H1 2025, while the company reported profit after tax of A$4.9 million and held A$287 million in cash and short-term investments at 30 June 2026.

The dividend's growth is being driven by strong underlying Demand for DAYBUE. Acadia reported global net sales of US$226 million for H1 2026, up 25% on the prior half, aided by adoption of DAYBUE STIX, a new powder formulation that reached 40% of all U.S. DAYBUE patients by 30 June 2026. Acadia has since increased its full-year 2026 global net sales guidance to US$480-510 million and reaffirmed a 2028 target of US$700 million. Geographically, the European Commission granted Marketing authorisation for DAYBU® across all 27 EU member states plus Iceland, Liechtenstein and Norway, with a German launch anticipated in early Q4 2026, while topline results from an ongoing Japanese trial are expected between September and November 2026.

Beyond DAYBUE, Neuren's pipeline candidate NNZ-2591 (ercanetide) continues to progress across multiple neurodevelopmental disorder programs. The Phase 3 "Koala" trial in Phelan-McDermid syndrome has grown from 2 to 15 active sites across the U.S. and Canada since the start of 2026, with 8 sites now activated for the open-label extension study. A Type B End of Phase 2 meeting with the FDA regarding Pitt Hopkins syndrome has been scheduled for late October 2026, and the U.S. Rare Pediatric Disease Priority Review Voucher program, relevant to NNZ-2591's three rare pediatric disease designations, was reauthorised by Congress through September 2029, with a comparable voucher recently selling for US$215 million.

Bull Case

H1 2026 royalty income grew 29% in US dollar terms, and Neuren now returns a substantial share of this income directly to shareholders via its new dividend policy, while still funding its full pipeline of NNZ-2591 development programs.

European launch of DAYBU® in Germany in early Q4 2026, Japanese trial results due September-November 2026, and continued DAYBUE STIX adoption in the U.S. all represent tangible, near-dated events that could further lift royalty income and Acadia's sales guidance.

NNZ-2591 carries orphan drug, Fast Track and Rare Pediatric Disease designations across three separate conditions, plus a fourth program in hypoxic ischemic encephalopathy, giving Neuren multiple shots at regulatory and commercial success beyond DAYBUE.

With A$287 million in cash and short-term investments, and all NNZ-2591 development activities already fully funded, Neuren is not reliant on near-term Capital raisings to progress its pipeline.

Bear Case

The overwhelming majority of Neuren's Revenue is derived from royalties on DAYBUE sales by Acadia Pharmaceuticals, a single drug, for a single approved indication, licensed to a third party the company does not control.

Neuren's hypoxic ischemic encephalopathy IND application has already been pushed from Q4 2026 to H1 2027 pending additional juvenile animal safety study data, and the FDA's initial feedback on the Pitt Hopkins syndrome trial design was considered by Neuren to be inappropriate, requiring further negotiation at the late-October meeting.

The 18 September ASX update itself reflects a degree of operational complexity in managing dividend payments across AUD and NZD-denominated shareholders, a reminder that execution details matter even in a well-performing company.

With the stock up around 80% over six months, much of the positive royalty growth and pipeline progress may already be reflected in the share price, raising the bar for future announcements to sustain momentum.

Key Takeaways

Neuren's steady climb on 18 September 2026 caps a strong six-month run built on rising DAYBUE royalty income and the launch of its first dividend program. With a well-funded pipeline and multiple near-term catalysts across Europe, Japan and the U.S., the stock remains a story worth watching, though its heavy reliance on a single licensed drug and an already elevated share price are factors investors should weigh.